Trial reportOncogene2007
Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling.
Trial report in Oncogene, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2012Guideline
- Prognostic Nomogram of Prognosis-Related Genes and Clinicopathological Characteristics to Predict the 5-Year Survival Rate of Colon Cancer Patients.Frontiers in surgery · 2021Article
- Identification and Clinical Validation of a Novel 4 Gene-Signature with Prognostic Utility in Colorectal Cancer.International journal of molecular sciences · 2019Article
- Evaluation of frozen tissue-derived prognostic gene expression signatures in FFPE colorectal cancer samples.Scientific reports · 2016Article
- Personalized identification of altered pathways in cancer using accumulated normal tissue data.Bioinformatics (Oxford, England) · 2014Article
- Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer.British journal of cancer · 2014Article
- Prognostic impact of genomic instability in colorectal cancer.British journal of cancer · 2014Article
- Review
- Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.Journal of cancer research and clinical oncology · 2012Article
- Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer.British journal of cancer · 2012Article
- Multiwalled carbon nanotube-induced gene signatures in the mouse lung: potential predictive value for human lung cancer risk and prognosis.Journal of toxicology and environmental health. Part A · 2012Article
- A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer.Molecular cancer therapeutics · 2012Article
- A network-based gene expression signature informs prognosis and treatment for colorectal cancer patients.PloS one · 2012Article
- Prediction of metastasis and recurrence in colorectal cancer based on gene expression analysis: ready for the clinic?Cancers · 2011Article
- Deletion of chromosome 4q predicts outcome in stage II colon cancer patients.Cellular oncology (Dordrecht, Netherlands) · 2011Article
- Article
- A breast cancer prognostic signature predicts clinical outcomes in multiple tumor types.Oncology reports · 2010Article
- Shrinkage-based diagonal discriminant analysis and its applications in high-dimensional data.Biometrics · 2009Article
- Genetic prognostic and predictive markers in colorectal cancer.Nature reviews. Cancer · 2009Review
- Preoperative chemoradiotherapy in locally advanced rectal cancer: correlation of a gene expression-based response signature with recurrence.Cancer genetics and cytogenetics · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have assessed the possibility to build a prognosis predictor (PP), based on non-neoplastic mucosa microarray gene expression measures, for stage II colon cancer patients. Non-neoplastic colonic mucosa mRNA samples from 24 patients (10 with a metachronous metastasis, 14 with no recurrence) were profiled using the Affymetrix HGU133A GeneChip. Patients were repeatedly and randomly divided into 1000 training sets (TSs) of size 16 and validation sets (VS) of size 8. For each TS/VS split, a 70-gene PP, identified on the TS by selecting the 70 most differentially expressed genes and applying diagonal linear discriminant analysis, was used to predict the prognoses of VS patients. Mean prognosis prediction performances of the 70-gene PP were 81.8% for accuracy, 73.0% for sensitivity and 87.1% for specificity. Informative genes suggested branching signal-transduction pathways with possible extensive networks between individual pathways. They also included genes coding for proteins involved in immune surveillance. In conclusion, our study suggests that one can build an accurate PP for stage II colon cancer patients, based on non-neoplastic mucosa microarray gene expression measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.